{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}],"title":"Mild (Grade 1)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"2"}]}],"title":"Moderate (Grade 2)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"0"}]}],"title":"Severe (Grade 3)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"5"}]}],"title":"Life-threatening (Grade 4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}],"title":"Death (Grade 5)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"17"},{"groupId":"OG008","value":"8"},{"groupId":"OG009","value":"7"}],"units":"Participants"}],"description":"Incidence and percentage of adverse events and serious adverse events will be collected from start of enrollment","groups":[{"description":"Participants received 1.8 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG000","title":"Dose 1"},{"description":"Participants received 3.6 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG001","title":"Dose 2"},{"description":"Participants received 7.2 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG002","title":"Dose 3"},{"description":"Participants received 12 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG003","title":"Dose 4"},{"description":"Participants received 18 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG004","title":"Dose 5"},{"description":"Participants received 27 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG005","title":"Dose 6"},{"description":"Participants received 40 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG006","title":"Dose 7"},{"description":"Participants received 60 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG007","title":"Dose 8"},{"description":"Participants received 80 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG008","title":"Dose 9"},{"description":"Participants received 60 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG009","title":"Melanoma Expansion Cohort"}],"paramType":"NUMBER","populationDescription":"All participants who received at least 1 dose of study treatment (KZR-261).","reportingStatus":"POSTED","timeFrame":"20 months","title":"Number and Percentage of Participants Experiencing Adverse Events as Assessed by CTCAE v5.0 (Part 1 & 2)","type":"PRIMARY","unitOfMeasure":"participants"}